Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSC | P53634 | 3/20 | 0.58 |
| ▸ | MC4R | P32245 | 1/20 | 0.56 |
| ▸ | DPP4 | P27487 | 1/20 | 0.55 |
| ▸ | TAAR1 | Q96RJ0 | 7/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | CA12 | O43570 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | CA9 | Q16790 | 1/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.45 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL18546544 | 0.99 | CTSC (0.57) | CTSCMC4RDPP4TAAR1NPSR1 | |
| SCHEMBL18554382 | 0.93 | KMT2A (0.58) | CTSCMC4RDPP4GAAMEN1 | |
| SCHEMBL18554400 | 0.93 | KMT2A (0.58) | CTSCMC4RDPP4GAAMEN1 | |
| SCHEMBL18554367 | 0.92 | KMT2A (0.54) | CTSCMC4RDPP4TAAR1NPSR1 | |
| Hydrochloric Acid SCHEMBL18546419 | 0.92 | KMT2A (0.60) | CTSCMC4RDPP4GAAMEN1 | |
| Hydrochloric Acid SCHEMBL18554483 | 0.92 | KMT2A (0.60) | CTSCMC4RDPP4GAAMEN1 | |
| SCHEMBL18546468 | 0.92 | KMT2A (0.54) | CTSCMC4RDPP4TAAR1NPSR1 | |
| SCHEMBL18556183 | 0.87 | CTSC (0.59) | CTSCMC4RDPP4NPSR1 | |
| SCHEMBL7067405 | 0.87 | CTSC (0.59) | CTSCMC4RDPP4NPSR1 | |
| SCHEMBL11170974 | 0.87 | MC4R (0.66) | MC4RDPP4TAAR1NPSR1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230287005-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | ACHILLION PHARMACEUTICALS, INC. | 2023-09-14 | — | — | US | disclosed |
| US-20230287005-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | ACHILLION PHARMACEUTICALS, INC. | 2023-09-14 | — | — | US | disclosed |
| US-10822352-B2 | Aryl, heteroaryl, and heterocyclic compounds for treatment of medical disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2020-11-03 | — | — | US | disclosed |
| US-10660876-B2 | Amino compounds for treatment of medical disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2020-05-26 | — | — | US | disclosed |
| US-10385097-B2 | Ether compounds for treatment of medical disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2019-08-20 | — | — | US | disclosed |
| US-20190211033-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2019-07-11 | — | — | US | disclosed |
| US-10287301-B2 | Aryl, heteroaryl, and heterocyclic compounds for treatment of medical disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2019-05-14 | — | — | US | disclosed |
| US-10011612-B2 | Aryl, heteroaryl, and heterocyclic compounds for treatment of medical disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2018-07-03 | — | — | US | disclosed |
| US-20180177761-A1 | AMINO COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2018-06-28 | — | — | US | disclosed |
| US-10000516-B2 | Phosphonate compounds for treatment of medical disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2018-06-19 | — | — | US | disclosed |
| US-20170066783-A1 | Aryl, Heteroaryl, and Heterocyclic Compounds for Treatment of Medical Disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2017-03-09 | — | — | US | disclosed |
| WO-2017035349-A1 | AMIDE COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2017-03-02 | — | — | WO | disclosed |
| US-20170057993-A1 | Ether Compounds for Treatment of Medical Disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2017-03-02 | — | — | US | disclosed |
| WO-2017035355-A1 | ETHER COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2017-03-02 | — | — | WO | disclosed |
| WO-2017035351-A1 | AMINO COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2017-03-02 | — | — | WO | disclosed |
| US-20170057993-A1 | Ether Compounds for Treatment of Medical Disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2017-03-02 | — | — | US | disclosed |
| US-20170057950-A1 | Amide Compounds for Treatment of Medical Disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2017-03-02 | — | — | US | disclosed |
| US-20170057983-A1 | Phosphonate Compounds for Treatment of Medical Disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2017-03-02 | — | — | US | disclosed |
| US-20170057950-A1 | Amide Compounds for Treatment of Medical Disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2017-03-02 | — | — | US | disclosed |
| US-20170057983-A1 | Phosphonate Compounds for Treatment of Medical Disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2017-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10822352-B2 | Aryl, heteroaryl, and heterocyclic compounds for treatment of medical disorders | CFD, F12, F3 | CTSC 473/4885MC4R 1733/4885DPP4 2144/4885 |
| US-20170066783-A1 | Aryl, Heteroaryl, and Heterocyclic Compounds for Treatment of Medical Disorders | CFD, F12, F3 | CTSC 473/4885MC4R 1733/4885DPP4 2144/4885 |
| US-20230287005-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | CFD, F12, F3 | CTSC 464/4885MC4R 1668/4885DPP4 2150/4885 |
| US-10011612-B2 | Aryl, heteroaryl, and heterocyclic compounds for treatment of medical disorders | CFD, F12, F3 | CTSC 473/4885MC4R 1733/4885DPP4 2144/4885 |
| US-20170057993-A1 | Ether Compounds for Treatment of Medical Disorders | CFD, TFPI, F12 | CTSC 1849/4885MC4R 2356/4885DPP4 3160/4885 |
| US-10385097-B2 | Ether compounds for treatment of medical disorders | CFD, TFPI, F12 | CTSC 1849/4885MC4R 2356/4885DPP4 3160/4885 |
| US-20170057983-A1 | Phosphonate Compounds for Treatment of Medical Disorders | CFD, TFPI, CFH | CTSC 1854/4885MC4R 3270/4885DPP4 2808/4885 |
| US-20190211033-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | CFD, F12, F3 | CTSC 473/4885MC4R 1733/4885DPP4 2144/4885 |
| US-10660876-B2 | Amino compounds for treatment of medical disorders | CFD, CFH, F12 | CTSC 506/4885MC4R 1649/4885DPP4 1500/4885 |
| US-10287301-B2 | Aryl, heteroaryl, and heterocyclic compounds for treatment of medical disorders | CFD, F12, F3 | CTSC 473/4885MC4R 1733/4885DPP4 2144/4885 |
| US-20180177761-A1 | AMINO COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | CFD, CFH, F12 | CTSC 506/4885MC4R 1649/4885DPP4 1500/4885 |
| US-20170057950-A1 | Amide Compounds for Treatment of Medical Disorders | CFD, TFPI, CFH | CTSC 868/4885MC4R 2470/4885DPP4 2634/4885 |
| US-10000516-B2 | Phosphonate compounds for treatment of medical disorders | CFD, TFPI, CFH | CTSC 1854/4885MC4R 3270/4885DPP4 2808/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.